Clinical trials: Advanced Malignant Tumors
Advanced Solid Tumor, Adult
Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib), in patients with eligible advanced solid tumors, determine the maximum tolerated dose…
- Trial name
- ATTACC (NCT04972110)
- Testing
- RP-3500 (camonsertib)
- Where
- 13 sites in United States
- Volunteers
- 156 people
- Sponsor
- Repare Therapeutics
Cancer, Neoplasms
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
IT141 is a novel nanoparticle formulation of SN-38, the active metabolite of irinotecan, and is intended to deliver more drug to the tumor with reduced toxicity on normal tissues.
- Conditions
- Cancer, Neoplasms, Tumors, Refractory Solid Tumors
- Trial name
- NCT03096340
- Testing
- IT-141
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Intezyne Technologies, Inc.
Solid Tumors, Lymphoma, Non-Hodgkin
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Part 1 and Part 2 of this trial will evaluate the safety, tolerability, maximum administered dose, and dose limiting toxicity of SCH 727965 administered every 3 weeks as a 2 hour intravenous (IV) infusion (Part 1), and as an…
- Conditions
- Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT00871910
- Testing
- SCH 727965, Aprepitant, Ondansetron
- Volunteers
- 81 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Pancreatic Cancer
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
This is a Japanese Phase 1, open-label, and dose-escalating trial of TH-302 as monotherapy in subjects with solid tumors and in combination with gemcitabine in subjects with pancreatic cancer.
- Trial name
- NCT01833546
- Testing
- Evofosfamide, Gemcitabine
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Solid Tumor, Metastatic Cancer
Study of GNX102 in Patients With Advanced Solid Tumors
GNX102 is a humanized monoclonal antibody (mAb), an engineered biotechnology product, developed by GlycoNex that targets certain cancer cells by binding with high affinity to specific structures on cancer cells.
- Conditions
- Solid Tumor, Metastatic Cancer, Advanced Cancer, Unresectable Solid Neoplasm
- Trial name
- NCT04250597
- Testing
- GNX102
- Where
- 8 sites in United States, Taiwan
- Volunteers
- 46 people
- Sponsor
- GlycoNex, Inc.
Advanced Solid Tumors
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in participants with advanced solid tumors.
- Trial name
- NCT05625412
- Testing
- BMS-986360, Docetaxel, Nivolumab
- Where
- 35 sites in United States, Argentina and 7 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignancies, Tumors
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
- Trial name
- NCT00421044
- Testing
- Patupilone/EPO906
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
The main aim of this study is to assess how the human body of adults with advanced or metastatic solid tumors absorbs, distributes, metabolizes and excretes subasumstat following a single 1 hour infusion of subasumstat.
- Trial name
- NCT05976334
- Testing
- [14C] Subasumstat, Subasumstat
- Where
- 2 sites in Hungary
- Volunteers
- 3 people
- Sponsor
- Takeda
Melanoma
Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma
The objective of the present trial is: to determine the dose limiting toxicity (DLT), maximal tolerated dose (MTD) and recommended phase 2 dose (RP2D) of intramuscular electrotransferred Plasmid AMEP in patients with advanced or…
- Trial name
- AIMM (NCT01764009)
- Testing
- naked DNA coding for protein AMEP
- Where
- 4 sites in France, Slovenia
- Sponsor
- Valerio Therapeutics
Tumors, Neoplasms
Phase I Study of LB-100 With Docetaxel in Solid Tumors
The purpose of this study is to test the safety of an investigational drug called LB-100 for Injection for treatment of solid tumors, when given with or without docetaxel.
- Conditions
- Tumors, Neoplasms, Cancer
- Trial name
- NCT01837667
- Testing
- LB-100 for Injection, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Lixte Biotechnology Holdings, Inc.
Advanced Malignant Tumor
An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor
This is an exploratory clinical study of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in patients with advanced malignant tumor.
- Trial name
- NCT04739111
- Testing
- Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Tumor, Solid
A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
The purpose of this study is to characterize the safety, tolerability, and efficacy of XNW29016 in participants with advanced solid tumors .
- Trial name
- NCT06987500
- Testing
- XNW29016
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Evopoint Biosciences Inc.
Melanoma
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
Study 1501-852A is a Phase 1 Study with the objective of determining safety and the highest tolerated dose of an immune response modifier cream directly applied to advanced, inoperable, melanoma skin lesions.
- Trial name
- NCT00091689
- Testing
- 852A
- Where
- 2 sites in United States
- Sponsor
- Pfizer
Advanced Colorectal Carcinoma
A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions
- Trial name
- NCT04645797
- Testing
- APR003
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Apros Therapeutics, Inc
Cervical Cancer
A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
This is a Phase 1/2, open-label study of zalifrelimab (AGEN1884) in combination with balstilimab (AGEN2034) in participants with locally advanced, recurrent and/or metastatic solid tumors including cervical cancer.
- Trial name
- NCT03495882
- Testing
- Zalifrelimab, Balstilimab
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 175 people
- Sponsor
- Agenus Inc.
Solid Tumors
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human…
- Trial name
- NCT03448042
- Testing
- Runimotamab, Trastuzumab, Tocilizumab
- Where
- 26 sites in United States, Australia and 11 more
- Volunteers
- 123 people
- Sponsor
- Genentech, Inc.
Advanced/Metastatic Solid Tumors
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .
- Trial name
- NCT04645069
- Testing
- ADG126 Mono, ADG126-anti PD1, ADG126-ADG106
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 58 people
- Sponsor
- Adagene Inc
Patients With Advanced Stage Solid Tumors
Phase I Study of Hemay102 in Patients With Advanced Solid Tumors
This trial was a single-center, open-label, dose-increasing Phase I clinical study with subjects enrolled in patients with advanced solid tumors who failed standard treatment or who were unable to receive effective treatment.
- Trial name
- NCT03982303
- Testing
- Hemay102
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Tianjin Hemay Oncology Pharmaceutical Co., Ltd
Solid Tumors
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This is an open-label, multicenter Phase 2 study evaluating Navlimetostat (BMS-986504) in participants with advanced and/or metastatic solid tumors that have MTAP deletion.
- Trial name
- NCT07492680
- Testing
- Navlimetostat, Daraxonrasib, Temozolomide
- Where
- 58 sites in United States, Belgium and 11 more
- Volunteers
- 254 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.